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Background. Ongoing characterization of glioma has
revealed that Akt signaling plays a crucial role in glioma-
genesis. In mouse models, however, Akt alone was not
sufficient to induce glioma.
Methods. We established transgenic zebrafish that
overexpressed dominant-active (DA) human Akt1 or
Rac1G12V (DARac1) at ptf1a domain and investigated
transgenic phenotypes and mechanisms leading to glio-
magenesis.
Results. Transgene expressions were spatiotemporally
restricted without any developmental abnormality of
embryos and persisted at cerebellum and medulla in
adult zebrafish. DAAkt1 alone induced glioma (with
visible bumps at the head), with incidences of 36.6%
and 49% at 6 and 9 months, respectively. Histologically,
gliomas showed various histologic grades, increased prolif-
eration, and frequent invasion into the fourth ventricle.
Preferential location of small tumors at periventricular
area and coexpression of Her4 suggested that tumors orig-
inated from Ptf1a- and Her4-positive progenitor cells at
ventricular zone. Gliomagenesis was principally mediated
by activation of survival pathway through upregulation
of survivin genes. Although DARac1 alone was incapable
of gliomagenesis, when coexpressed with DAAkt1,
gliomagenesis was accelerated, showing higher tumor inci-
dences (62.0% and 73.3% at 6 and 9 months, respective-
ly), advanced histologic grade, invasiveness, and shortened
survival. DARac1 upregulated survivin2, cyclin D1,
b-catenin, and snail1a but downregulated E-cadherin,
indicating that DARac1 promotes gliomagenesis by
enhancing proliferation, survival, and epithelial-to-
mesenchymal transition. On pharmacologic tests, only
Akt1/2 inhibitor effectively suppressed gliomagenesis,
inhibited cellular proliferation, and induced apoptosis in
established gliomas.
Conclusions. The zebrafish model reinforces the pivotal
role of Akt signaling in gliomagenesis and suggests Rac1
as an important protein involved in progression.
Keywords: Akt1, epithelial-mesenchymal transition, gli-
oma, Rac1, transgenic zebrafish.
P
rimary brain tumors account for 1.4% of all
cancers and 2.4% of all cancer-related deaths in
the United States, and malignant gliomas account
for 70% of malignant primary brain tumors.1
Glioma can be classified histologically from grade I to
grade IV, according to World Health Organization
(WHO) criteria, with glioblastoma (grade IV) accounting
for 70% of malignant gliomas.2 Primary glioblastoma is
predominant, with 10% being secondary glioblastoma
formed by progression of pre-existing low-grade glioma.
Glioblastomas are formed by the sequential accu-
mulation of genetic alterations, including the loss of
the tumor-suppressor function, deregulation, and acti-
vation of growth factor signaling and activation of the
survival pathway.1,3 Although molecular signatures
vary between primary and secondary glioblastomas,
p16, p53, retinoblastoma, and PTEN are among the
genes most frequently lost in glioblastoma. Deregula-
tion of growth factor signaling includes overexpression
or activating mutations of platelet-derived growth
factor (PDGF), PDGF receptor, epidermal growth
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factor receptor (EGFR), mouse double minute-2
(mdm2), CDK4, and PI3K.4,5 These alterations most
often result in the activation of the Akt pathway.
Akt (also known as PKB), a serine-threonine protein
kinase, is a key mediator of the phosphatidylinositol
3-kinase (PI3K)-Akt-mammalian target of rapamycin
(mTOR) signal pathway, which is activated in up to
90% of all glioblastomas.6 The activation of Akt signal-
ing can be initiated by PTEN inactivation, PI3K activa-
tion, or upregulation of growth factors.7,8 Studies of
Akt have showed its involvement in such diverse physio-
logical actions as nutrient metabolism, protein synthesis,
cell survival, transcriptional regulation, the cell cycle,
cell apoptosis, and proliferation. The anti-apoptotic
signal is largely mediated by phosphorylation resulting
in the inhibition of Bad, caspase-9, and forkhead tran-
scriptional factor and the activation of I-kB kinase and
Mdm2.9,10 Akt has also been identified as a positive reg-
ulator of the survivin gene,11 which is a member of the
inhibitors of apoptosis (IAP) family expressed during
embryonic development but not in terminally differenti-
ated adult tissues.12–14 Subsequent studies have revealed
that survivin is re-expressed in transformed cell lines and
in a variety of human tumors and is essential for the anti-
apoptotic function.15,16 mTOR plays a key role in medi-
ating Akt-induced cell proliferation. Activated mTOR
complex activates ribosomal protein S6 kinase (RS6K)
and inactivates the eukaryotic translation initiation
factor 4E binding protein 1 (4EBP1), which inhibits eu-
karyotic translation initiation factor 1 (Eif1a). Akt also
inhibits GSK3b, which acts as a negative regulator of
cell cycle progression through inhibition of cyclin
D1.17,18
Rho GTPase family proteins mediate distinct cyto-
skeletal rearrangements in response to receptor stimu-
lations and have been implicated in the establishment
and maintenance of cadherin-based cell-cell adhe-
sions.19,20 Rac is a member of this family and counter-
acts Rho activity. The reciprocal balance between Rho
and Rac activity is a major determinant of cellular
morphology and motility.21 Active Rac1 signaling is
associated with acquiring the mesenchymal phenotype
of cancer cells and with enhanced motility and inva-
sion.22,23 In vitro studies have shown that suppression
of Rac1 activity is associated with the immobilization
and induction of apoptosis of glioma cells.24,25 In
addition, Rac1 controls the nuclear localization of
b-catenin by phosphorylation, which induces cell
proliferation.26
Although evidence has been reported on the critical
role of Akt signaling in gliomagenesis, the expression
of Akt alone was insufficient to induce glioma in
mouse models3,27; coactivation of Kras signaling was
needed to induce glioblastoma. In the current study,
we established transgenic zebrafish expressing dominant-
active (DA) DAAkt1 or DARac1 at the ptf1a domain.
We found that DAAkt1 alone induced glioma, and this
process was accelerated by coexpression of DARac1;
the relevant mechanism in which Akt1 and Rac1 are




We used Ptf1aGal4 fish previously established for targeted
expression of transgenes under the regulation of the up-
stream activating sequence (UAS) by a binary expression
system (Fig. 1A).28,29 Human DAAkt1 (1036 pcDNA3
Myr-HA-Akt1; myristoylated AKT1 targeted to the
membrane independently of PtdIns-3,4,5-P3 and referred
to as dominant-active human AKT1) was purchased from
Addgene (Cambridge, MA), and human Rac1 cDNAwas
purchased from Open Biosystems (Huntsville, AL).
With use of polymerase with a proofreading function
(Invitrogen, Grand Island, NY), a green fluorescent
protein (GFP) sequence including a polyA site was poly-
merase chain reaction (PCR) amplified from pEGFP1
vector (Clontech, Mountain View, CA) using F-GFP-
Nco1/R-GFPpA-Xho1 primers. The PCR product was
digested and inserted into the Nco1/Xho1 sites of
JD21:UAS-GFP-Kras (a generous gift from Steven
D. Leach) to generate JD21:UAS-GFPpA-Kras. DAAkt1
was PCR amplified using F-DAAkt1-Nco1/R-DAAkt1-
Cla1 primers, digested, and inserted into Nco1/Cla1
sites of JD21:UAS-GFP-Kras to generate JD21:UAS-
DAAkt1. Then, the UAS-DAAkt1 sequence was PCR
amplified using F-UAS-Xho1/R-DAAkt1-Cla1, digested,
and inserted into the Xho1/Cla1 sites of JD21:UAS-
GFPpA-Kras to generate the final transgene construct,
JD21:UAS-GFP-UAS-DAAkt1 (Fig. 1A). For targeted ex-
pression of DARac1G12V, Rac1 was PCR amplified using
F-Rac1(G12V)-Nde1/R-Rac1-Cla1, digested, and insert-
ed into theNde1/Cla1 site of JD21:UAS-GFP-Kras to gen-
erate JD21:UAS-GFP-DARac1 (Fig. 1A). In this construct,
theDARac1 is expressed as a fusionproteinwithGFP.The
coexpressed GFP was intended to enable real-time obser-
vation. A control construct was generated by digesting
JD21:UAS-GFPpA-Kras with Xhol1/Cla1, blunting, and
then self-ligation. JD21:UAS-mCherrypA was generated
by replacing GFP of JD21:UAS-GFPpA with mCherry.
All constructswere sequence verified using the appropriate
primers. Primers used for transgene constructs are listed in
Supplementary Table S1.
Each injection mixture was made by reconstituting
Tol2-transposase mRNA (20 ng/mL) and a transgene
construct (20 ng/mL) in Danieu’s buffer mixed with
0.03% phenol red. Single-cell stage Ptf1aGal4 embryos
were transferred to a molded agarose dish, and 4 pL of
the injection mixture was introduced by yolk injection
with use of a MMPI-2 microinjector. Approximately
50% of the injected embryos survived. On day 2, fluores-
cence was monitored using an Olympus inverted fluores-
cence microscope, and F0 founder embryos showing
green fluorescence at the Ptf1a domain were selected.
For each transgene construct, 100 founder embryos
were raised until adulthood and outcrossed to generate
F1 transgenic zebrafish (Fig. 1). The use of Tol2-
mediated transgenesis greatly enhanced the transgenic
efficiency, such that 25%–50% of F0 zebrafish from
each construct produced F1 offspring expressing
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transgenes. In each clutch of F1 embryos, 10% showed
transgene expression. Among the F1 progenies, embryos
showing faithful expression were selected and raised to
produce F2 progenies. All transgenes were transmitted
in normal Mendelian ratios. Through outcrossing with
AB lines, all experiments were performed using zebrafish
heterozygous for each transgene.
Animal Stocks and Embryo Care
All zebrafish were raised in a standardized aquarium
system (Genomic-Design Co., Daejeon, Korea) accord-
ing to standard protocols at 288C on a 14:10-h light-
dark cycle. The mitfaw2; roya9 (AB) zebrafish were
purchased from Zebrafish International Resource Center
Fig. 1. Targeted expression of transgenes in embryos. (A) Transgenesis strategy. Gal4-UAS system allows targeted expression of transgenes.
(B) Inverted fluorescence images (upper column, dorsal views; lower column, lateral views). Transgenic GFP expression is spatiotemporally
restricted to the Ptf1a domain. Exocrine pancreatic expression of DARac1 disturbs the posterior expansion of the exocrine pancreas. The
morphology of the hindbrain is not altered by either DAAkt1 or DARac1 expression. (C) Whole-mount ISH at 2 dpf (dorsal views) and
4 dpf (lateral views). (D) Confocal images showing membrane localization of GFP fused with DARac1. Abbreviations: H, hindbrain;
R, retina; P, exocrine pancreas. Bars, 20 mm.
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Fig. 2. Transgene expression in juvenile and adult zebrafish. (A) Merged bright and fluorescence images showing GFP expression at the
cerebellum and medulla. Depigmented phenotypes were obtained by successive crossing with the mitfaw2;roya9 line. Although
1-month-old zebrafish showed sustained GFP expression at the cerebellum and medulla, transgene expression was more localized at the
cerebellum at 3 months. The top is anterior. Inlets are lateral views. (B) ISH for Ptf1a and transgenes. Transgene expression is stronger at
the intermediate layer and the ventricular zone. Inlets are enlarged views of the ventricular area. (C) Coronal images of 1-month-old
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(ZIRC, Eugene, OR). GFAPGFP,30 Her4RFP,31 and
Olig2RFP32 transgenic fish were kind gifts from Hae-Chul
Park. Embryos to be processed for whole-mount analyses
were placed inE3mediumwith0.003%phenylthiourea at
24 h after fertilization to inhibit pigmentation.We strictly
followed the Guidelines for the Welfare and Use of
Animals in Cancer Research.33
Histology, Immunohistochemistry, In Situ
Hybridization, and Immunofluorescence
Histologic evaluation was performed using 4-mm sec-
tions of 4% paraformaldehyde-fixed, paraffin-embed-
ded tissues. Hematoxylin and eosin staining was
performed according to standard protocols.34 Gene ex-
pression analyses were performed either by immunohis-
tochemistry (IHC), if an antibody cross-reactive to
zebrafish was available, or by in situ hybridization
(ISH), as previously described.29,34 Primary antibodies
were as follows: rabbit anti-Akt1 (1:500), mouse
anti-Rac1 (1:500), mouse anti-proliferating cell nuclear
antigen (PCNA) (1:2000), and rabbit anti-pancadherin
(1:500) from Abcam (Cambridge, MA); rabbit
anti-GFAP (1:200), rabbit anti-snail1a (1:500), rabbit
anti-b-catenin1 (1:200), rabbit anti-caspase a (1:500),
and rabbit anti-caspase b (1:500) from Anaspec
(Fremont, CA, USA); and rabbit anti-phospho-histoneH3
(pHH3; 1:200), rabbit anti-phospho-mTOR (1:200),
rabbit anti-phospho-4EBP1 (1:200), and rabbit anti-
phospho-RS6K (1:200) from Cell Signaling (Danvers,
MA). HRP-conjugated secondary antibodies were used
and colored using diaminobenzidine solution. For labeling
with 5-bromo-2′-deoxyuridine (BrdU), 2-month-old
zebrafish were deprived of food for 24 h, bathed in a 1-L
water tank containing 0.5% BrdU (Sigma-Aldrich,
St. Louis,MO) for 2 h, rinsed, kept for 48 h, and processed
for IHC, as previously described,35 with use of mouse
anti-BrdU antibody (1:200; Dako, Gostrup, Denmark).
Slides were counterstained with hematoxylin and
mounted with Histomount (Zymed, San Francisco, CA).
Riboprobes were generated by PCR amplification of
coding sequences from cDNA, TA cloning into pCRII
vector (Invitrogen), and in vitro transcription. Primers
used for TA cloning are listed in Supplementary Table
S2. Hybridized embryos or sections were bound with
an alkaline phosphatase-conjugated anti-digoxigenin
antibody and colored using an NBT/BCIP solution.
Sections were counterstained with neutral red and
mounted with Histomount.
Immunofluorescence was performed using 8-mm
cryosections of 4% paraformaldehyde-fixed tissues as
previously described.36 Cryosections were incubated over-
night in 10% goat serum with rabbit anti-S100 (1:400;
Dako) antibody, washed with PBST, and then incubated
overnight in 10% goat serum with a Cy3-conjugated
secondary antibody (Jackson Labs, West Grove, PA).
Imaging
An Olympus MVX10 fluorescence microscope was used
for whole-mount embryo imaging. Photographs from
slide sections or live embryos were obtained using an
Olympus BX51 microscope or a Carl Zeiss 700 confocal
microscope.
Reverse-Transcription PCR
Real-time PCR was performed using dissected brain
tissue from 3-month-old zebrafish. The coexpressed
GFP enabled precise dissection of brain tissue. For
each group, samples were collected from 3 or 4 zebrafish
and used for total RNA extraction, followed by cDNA
reverse transcription. Reverse-transcription (RT) PCR
was performed as previously described29,34 with use of
the 7300 Real Time PCR System (Applied Biosystems,
Foster City, CA) with the QuantiTectTMSYBR Green
PCR Kit (Qiagen, Valencia, CA). Samples were analyzed
in triplicate, and all experiments were performed three
times with use of separately prepared samples. Primer
sequences for RT-RCR are shown in Supplementary
Table S3.
Treatment with Akt Pathway Inhibitors
To counteract active Akt signaling in live zebrafish, rapa-
mycin (mTOR inhibitor; IC50 50 pM; Sigma-Aldrich
A8781), miltefosine (interferes with membrane localiza-
tion of Akt; IC50 3–25 mM; Sigma-Aldrich M5571),
37
and Akt1/2 inhibitor (kinase inhibitor; IC50 58 nM
for Akt1, 210 nM for Akt2; Sigma-Aldrich A6730)38
were used. To determine treatment doses, 2-week-old
embryos were treated with a serial escalation of each in-
hibitor for 7 days. We selected maximum tolerated doses
(MTDs) that caused fatality rates of no more than 25%,
which were 200 nM, 1 mM, and 500 nM for rapamycin,
miltefosine, and Akt1/2 inhibitor, respectively. First,
groups of 2-week-old Ptf1aGal4/UASGFP-UASDAAkt1
larvae (32 per group) were separately treated with the
Ptf1aGal4/UASGFP zebrafish of (A). (b) GFP expression is robust along the midline and at the dorsal lining of the fourth ventricle. (D)
Immunofluorescence for S100 at the similar plane level of (Cb). S100-positive cells are concentrated at the ventral lining of the fourth
ventricle and the intermediate layer and scattered in the granular layer. Strong Ptf1a expression (GFP) persists in cells at intermediate
layer, ventricular zone, and along the midline. Images reveal cerebellar cells positive for either GFP or S100 (red arrowheads) alone or for
both (white arrowheads). (E–G) Coexpression analyses. During embryonic development, Ptf1a expression is noted in cells at the dorsum
of cerebellum and inferior olive nucleus (IO). (E) GFAPGFP/Ptf1aGal4/UASmCherry zebrafish. Most cells expressing Ptf1a (RFP) also express
GFAP (GFP). (F) Olig2dRFP/Ptf1aGal4/UASGFP zebrafish. Cerebellar cells do not coexpress Olig2 and Ptf1a both in embryo and adult. (G)
Her4dRFP/Ptf1aGal4/UASGFP zebrafish. During embryonic development, ptf1a-positive cells (GFP) are at just underneath Her4-expressing
(RFP) cells and rarely coexpress Her4. In adults, Ptf1a-positive cerebellar cells at ventricular and supraventricular areas occasionally
coexpress both Ptf1a and Her4. Bars, 50 mm.
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Fig. 3. DAAkt1-induced gliomas. (A) Gross and histologic findings. (a,b) Glioma-bearing 3-month-old Ptf1aGal4/UASGFP-UASDAAkt1
zebrafish with bent body and visible bumps at the head, showing strong GFP expression on merged bright and fluorescence images
(inlets). (c) Hematoxylin and eosin stains of cerebellum in control zebrafish. (d–i) Hematoxylin and eosin stains of gliomas. (d and e)
Small tumors (boundaries by red arrowheads) at periventricular area showing invasion into 4th ventricle. (f) A large glioma replacing
almost the whole cerebellum. (g) A large glioma showing invasion into the midbrain. (h) A high-grade glioma showing increased
vascularity (black arrowhead). (i) A high-grade glioma showing necrosis (red arrowhead). (j) IHC for GFAP showing robust expression.
(k) IHC for Akt1 on a small tumor invading 4th ventricle showing expression at tumor. (l) ISH for DAAkt1 showing stronger expression
at the hypercellular area. (B) Increased proliferation in DAAkt1-induced gliomas. IHC indicates highly frequent positivity to PCNA, which
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MTD of each inhibitor in 1-L water tanks up to 8 weeks
and then processed for histology. Next, groups (3 per
group) of 3-month-old Ptf1aGal4/UASGFP-UASDAAkt1
zebrafish having overt brain tumors were treated for
10 days and then processed for histologic evaluation.
During the course of treatment, tank water was refreshed
daily and inhibitors were newly added.
Statistical Analyses
Statistical analyses were performed using SPSS, version
11 (SPSS); P, 0.05 was considered to indicate a statisti-
cally significant difference.
Results
Transgene Expression in Embryos and Adult Zebrafish
Multiple independent transgenic lines were established:
7 for Ptf1aGal4/UASGFP-UASDAAkt1, 8 for Ptf1aGal4/
UASGFP-DARac1, and 7 for Ptf1aGal4/UASGFP. Binary ex-
pression by a Gal4-UAS system allowed faithful expres-
sion of transgenes at the ptf1a domain (Fig. 1B and C).
The expression levels, when estimated by GFP expres-
sion, were different among the F1 progenies, depending
on their parental zebrafish. By selecting F1 embryos with
faithful and robust expression of transgenes, we success-
fully established stable lines.
In DAAkt1- and DARac1-expressing embryos, hind-
brain morphologies did not differ from those of
control embryos. Exocrine pancreas in DARac1-
expressing embryos, however, revealed morphological
changes: the posterior growth of the exocrine pancreas
was retarded, revealing a doughnut-shaped exocrine
pancreas circumscribing the principal islet even at 5
days after fertilization. This phenotype might be attrib-
utable to the DARac1-induced cytoskeletal derange-
ment, but detailed pancreatic phenotypes were beyond
the scope of this study and were not further explored.
The precise expression domain of ptf1a has not yet
been characterized. During embryonic development,
Ptf1a expression was noted in cells at the dorsum of
the cerebellum and inferior olive nucleus (Figs 1 and
2E). Although hindbrain expression of ptf1a has been re-
ported to gradually decrease from 72 h after fertilization
in zebrafish,39 we observed persistent expression at the
cerebellum and medulla based on the observation of
GFP expression (Fig. 2). Transgene expression was espe-
cially robust in cells along the midline of the cerebellum
and at the intermediate layer and ventricular zone
(dorsal lining of fourth ventricle), which has been
assumed to be a niche for progenitor cells. Immuno-
fluorescence revealed that a small proportion of ptf1a-
positive cells expressed an astrocyte marker, S100
(Fig. 2D).
For further clarification, we performed coexpression
analyses by crossing them with transgenic lines express-
ing biomarkers at the GFAP, Her4, or Olig2 domain.
Most Ptf1a-positive cerebellar cells also expressed
GFAP from embryo to adulthood (Fig. 2E). Olig2 ex-
pression, however, was not noted in Ptf1a-positive cells
(Fig. 2F). Although Ptf1a-positive cells rarely coex-
pressed Her4 in embryos, cells at the supraventricular
and ventricular zone occasionally coexpressed both
ptf1a and Her4 in adult cerebellum (Fig. 2G).
Ventricular Her4-positive cells have been assumed to
be neuronal progenitors that proliferate after injury
and produce neural cells in the adult zebrafish
brain.40,41 The aforementioned findings suggest that
ventricular ptf1a-positive cells encompass progenitor
cells that can produce neuronal and glial cells.
DAAkt1 Induces Glioma of Various Histologic Grades
At 2 months of age, some of the DAAkt1-expressing
zebrafish started to show morphologic changes in their
body configuration. Their body became bent and then
gradually tortuous. Approximately 1 month later, fish
started to show visible bumps on the head, which had
strong GFP expression (Fig. 3A and B). The bending of
the body seemed to be attributable to motor disturbance
caused by a tumor formed in the cerebellum. Because
body bending always preceded the appearance of a
visible tumor, we considered this phenotype to be a sur-
rogate marker. On the basis of this surrogate marker,
tumor incidence rates were 36.6% and 49% at 6 and 9
months, respectively.
In histologic evaluation, the zebrafish with bent
bodies invariably had tumors at the cerebellum
(Fig. 3A). The tumors were gliomas immunoreactive to
GFAP, with a robust expression of Akt1 and histologic
grades varying from I to IV according to the WHO clas-
sification. Larger tumors tended to have advanced histo-
logic grades. High-grade tumors invariably showed
hypercellularity, increased vascularity, and frequent
mitosis, with occasional necrosis in 10% of tumors.
Necrosis was infrequently observed because tumor-
bearing zebrafish died of tumor before the tumor grew
large enough for the development of necrosis. Advanced
tumors frequently revealed various histologic grades in a
tumor, showing areas with hypercellularity and a more
robust expression of DAAkt1.
is even higher in high-grade tumor. Tumors occasionally show positive staining to PHH3, a mitotic marker. BrdU labeling also reveals
frequently positive cells. (C) Proliferation analyses in the pre-neoplastic cerebellum of 2-month-old zebrafish. Reactivity at the intestinal
cells is used as an internal positive control (Inlets). Cells at the ventricular lining and the intermediate layer frequently reveal
immunoreactivity to proliferative markers. The non–tumor-bearing cerebellum of DAAkt1-expressing zebrafish is not associated with
increased proliferation. Average numbers of positive cells counted at the periventricular are 4.5+2.2 and 4.7+2.6 for PHH3 and
18.7+6.8 and 19.9+6.9 for BrdU in Ptf1aGal4/UASGFP and Ptf1aGal4/UASGFP-UASDAAkt1 zebrafish, respectively, which are not
significantly different. Bars, 50 mm. (D) Activation of Akt downstream components in nonneoplastic DAAkt1-expressing cerebellum. IHC
analyses reveal slightly increased expression of phospho-mTOR, -RS6K, and -4EBP1 in cells at the ventricular and periventricular zone.
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Fig. 4. DARac1 accelerates DAAkt1-induced glioma. (A) Two-month-old zebrafish showing bumps at the head. Inlets are merged bright
field and fluorescence images. (B) Histologic findings of gliomas in Ptf1aGal4/UASGFP-UASDAAkt1/UASGFP-DARac1 zebrafish. (a-g)
Hematoxylin and eosin staining. Tumors frequently reveal heterogeneous grade of glioma showing a hypercellular nest within the tumor
(red arrowheads) and increased vascularity (black arrowheads). (g and h) IHC and ISH for transgenes in a high-grade glioma. Inlets of
(g) and (h) are IHC for Akt1 and ISH for DARac1, respectively. (i and j) ISH for DARac1. Cells at the invasion front show stronger
expression of DARac1. Arrows indicate the direction of invasion. (k and l) Proliferation analyses reveal increased positivity to PCNA and
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Gliomas Originate from Ptf1a- and Her4-Positive
Progenitor Cells at the Ventricular Zone
Small tumors were invariably located at the vicinity of
the fourth ventricle, showing disruption of the ventricu-
lar lining and a space-occupying mass in the ventricle
(Fig. 3A). As a tumor grew, it gradually replaced the
whole cerebellum and invaded the midbrain. For
lineage evaluation, DAAkt1-expressing zebrafish were
outcrossed to express RFP in the Her4 or Olig2
domain (Supplementary Fig. 2). Most of the
DAAkt1-positive glioma cells also expressed Her4 but
not Olig2. Taking into consideration that Her4-positive
cells are neuronal progenitors in zebrafish brain, the
aforementioned findings suggest that the tumor originat-
ed from Ptf1a- and Her4-expressing progenitor cells
at the ventricular zone, which is known as a putative
stem cell niche in the brain.42
DAAkt1 Expression Induced Akt Signaling Without
Enhanced Proliferation
In the cerebellum of the control and DAAkt1-expressing
zebrafish, proliferating cells were principally located at
the ventricular zone and intermediate layer, where trans-
gene expression was also robust (Figs 2B and 3C).
DAAkt1-induced glioma cells showed a striking increase
in cellular proliferation (Fig. 3B). However, non–tumor-
bearing cerebellum from DAAkt1-expressing zebrafish
did not show increased proliferation, compared with
control (Fig. 3C). To see Akt signaling activation, we
evaluated phosphorylated downstream components by
IHC in preneoplastic cerebellum. In contrast to the
GFP expression shown on confocal imaging and the
DAAkt1 expression shown by ISH, activation of down-
stream components was noted in a small subset of cells
at the ventricular and periventricular zone, showing an
increased number of cells positive for pmTOR and
pRS6K but not for p4EBP1 (Fig. 3D). However, an es-
tablished glioma revealed strong expression of those
active downstream proteins of Akt signaling (Fig. 6B).
This finding suggests that DAAkt1-induced gliomagenesis
occurs in the subset of cells in which active Akt signaling
has been induced by DAAkt1 expression in this model.
Coexpression of DARac1 Accelerates DAAkt1-Induced
Tumorigenesis
Rac has been implicated in the migration and invasion of
glioma cells.23,26 In the current model, DARac1 alone
did not induce brain tumors during the 18-month
follow-up. When DARac1-expressing zebrafish were
crossed with DAAkt1-expressing fish to produce coex-
pression, gliomagenesis was greatly accelerated. On the
basis of the surrogate marker, incidence rates were
44.4% at 3 months, 62.0% at 6 months, and 73.3%
at 9 months (Fig. 4D). The coexpression of DARac1
not only enhanced tumor incidence but also increased
histologic grade and invasiveness. The proportions of
high-grade tumor (grade III or IV) were 48.4% and
67% at 3 and 6 months, respectively (Fig. 4C).
Frequently, individual high-grade tumors showed het-
erogeneous histologic grades, manifested as intratu-
moral cell nests with increased cellularity (Fig. 4B); the
intratumoral cell nests further revealed an increase in
reactivity to proliferative markers and more robust ex-
pression of transgene DARac1 (Fig. 4C). Tumor cells
at the invasion front showed more robust expression of
DARac1 (Fig. 4C), suggesting enhanced invasiveness
by coexpression of DARac1. This accelerated glioma-
genesis and invasiveness resulted in earlier and higher
mortality by DARac1 coexpression (Fig. 4D).
Differentially Expressed Genes
We selected a list of genes that might be modulated by
the aberrant expression of DAAkt1 and DARac1.
Among the genes evaluated, survivin1 and p21 were
upregulated by DAAkt1 expression in non–tumor-
bearing zebrafish. DAAkt1-induced glioma resulted in
significant upregulation of p21, cyclin D1, survivin1,
survivin2, and snail1a, compared with the control
brain tissue (Fig. 5A and B). Coexpression of DARac1
was associated with striking upregulation of survivin2
and snail1a, modest upregulation of cyclin D1 and survi-
vin1, and downregulation of E-cadherin. Western blot
analyses confirmed the RT-PCR findings (Fig. 5C).
This finding suggested that activation of survivin genes
played an important role in the current model and that
snail1a upregulation was involved in DARac1-induced
acceleration of gliomagenesis.
Next, expression patterns were evaluated at the histo-
logic level (Fig. 5D). Gliomas coexpressing DAAkt1 and
DARac1 showed higher expressions of b-catenin, cyclin
D1, and survivin2, especially at intratumoral hypercellu-
lar nests, compared with tumors expressing DAAkt1
alone. Snail1a expression was also increased by coex-
pression of DARac1, especially at the invasion front
and hypercellular area. Although the expressions of pan-
cadherin andE-cadherinwere downregulated,N-cadherin
expression was increased by coexpression of DARac1.
These findings suggest that DARac1 further enhanced
PHH3, especially at the hypercellular areas, which accompanies a more robust expression of DARac1 on ISH (inlet). (C) Histologic grade of
gliomas. Coexpression of DARac1 increased not only the tumor incidence but also the histologic grades of gliomas (D) Tumor incidence and
mortality. 112 zebrafish from each Ptf1aGal4/UASGFP-UASDAAkt1 and Ptf1aGal4/UASGFP-UASDAAkt1/UASGFP-DARac1 line were followed. Tumor
incidence was estimated by body bending, which preceded the appearance of an obvious bump in the head. The incidence rates of glioma in
Ptf1aGal4/UASGFP-UASDAAkt1 and Ptf1aGal4/UASGFP-UASDAAkt1/UASGFP-DARac1 zebrafish are 14.3% and 44.4% at 3 months, 36.6% and
62.0% at 6 months, and 49.1% and 73.2% at 9 months, respectively. The mortality rates are also increased by the coexpression of
DARac1: 0.9% vs. 22.2% at 3 months, 15.2% vs. 50.9% at 6 months, and 21.4% vs. 60.2% at 9 months. The tumor-free survival
rates are much lower in the Ptf1aGal4/UASGFP-UASDAAkt1/UASGFP-DARac1 line. Bars, 50 mm.
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Fig. 5. Differential genes involved in gliomagenesis. (A) Real-time RT-PCR using dissected glioma and control cerebellum shows changes in
transcripts. Survivin1 and p21 are upregulated in pre-neoplastic cerebellum by DAAkt1 expression. DAAkt1-induced glioma shows
upregulation of cyclin D1, p21, Survivin1, 2, and snail1a. Coexpression of DARac1 reveals further upregulation of survivin2 and snail1a,
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cell proliferation and survival, along with cell migration
and invasion, through epithelial-mesenchymal transition
(EMT) by snail1a induction and through altering
cell-to-cell adhesion.
Akt1/2 Inhibitor Suppressed Glioma Formation
Each group of 14-day-old DAAkt1-expressing larvae
was treated with Akt pathway inhibitors up to 2
months of age. Prolonged treatment increased mortality
rates, which were 9.4% (3/32), 15.6% (5/32), 28.1%
(9/32), and 37.5% (12/32) for control, miltefosine,
rapamycin, and Akt1/2 inhibitor, respectively. Akt1/2
inhibitor was effective in suppressing glioma formation
(Fig. 6A), showing a 23.3% point decrease of tumors.
Miltefosine or rapamycin treatment, however, was
not preventive for gliomagenesis. Next, we treated
3-month-old adult zebrafish with established tumors
with these agents for 10 days. Although none of these
3 agents resulted in tumor shrinkage, Akt1/2 inhibitor
increased the number of tumor cells positive for active
caspases (Fig. 6C). Proliferation analysis showed that
both Akt1/2 inhibitor and rapamycin significantly
reduced the number of tumor cells reactive to PCNA
(Fig. 6B and D). The ineffectiveness of miltefosine prob-
ably resulted from an insufficient dose because of dose-
limiting toxicity (MTD. 1 mM). Rapamycin effectively
suppressed mTOR activation (Fig. 6B) and decreased
PCNA-positive cells (Fig. 6C and D) but did not
prevent gliomagenesis. These findings suggest that en-
hanced survival but not proliferation mediated by
mTOR played a key role in Akt1-induced gliomagenesis
in this model, which was more likely because of the pref-
erential deregulation of survival genes found on
RT-PCR.
Discussion
To our knowledge, this is the first study reporting that
the targeted expression of DAAkt1 at the ptf1a
domain alone initiates gliomagenesis in the zebrafish cer-
ebellum. The tumor incidence was high, with half of
DAAkt1-expressing zebrafish exhibiting glioma at 9
months of age. The discrepancy between zebrafish and
a mammalian model may be attributable to the inherent
susceptibility of zebrafish to Akt1-induced gliomagene-
sis or the different transgenic strategies used in the
current model, which allowed faithful and robust ex-
pression by the GAL4-UAS system. DAAkt1 transgenic
zebrafish made it possible to study single gene-mediated
tumorigenesis, which allows a more straightforward
approach to elucidating the pivotal role of Akt signaling
and its molecular events in glioma formation.
Unfortunately, antibodies reactive to zebrafish antigens
are rarely available, and thus, it was impractical to inves-
tigate all Akt signaling targets; among the long lists of
humanized antibodies against Akt downstream compo-
nents, anti-pmTOR, anti-pRS6K, and anti-p4EBP1
were active only for IHC but not for Western blot.
Akt has multiple targets and is involved in mediating
various biological responses, including cell proliferation,
cytoskeleton, and survival, and transcription, protein
synthesis, and nutrient metabolism, all of which are im-
plicated in the process of tumorigenesis.8,10,43,44 Recent
studies have suggested that PI3K-Akt signaling plays a
crucial role in glioma formation and progression.43
PTEN inactivation frequently occurs in glioma, either
by deletion, mutation, or promoter methylation, result-
ing in downstream activation of Akt signaling.7,45,46
Amplification of PDGFR or EGFR frequently occurs in
glioma and also leads to Akt activation.
In the current model, we aberrantly expressed
DAAkt1 at the Ptf1a domain in zebrafish. Ptf1a expres-
sion is induced in the hindbrain, spinal cord, retinal, and
the exocrine pancreas during embryonic development in
zebrafish. However, the precise cellular compartment of
ptf1a expression in the brain has not yet been defined.
Our current study revealed a persistent and strong ex-
pression of ptf1a in the cells at the ventricular zone
and intermediate layer. Most of the ptf1a-positive cells
were also positive for GFAP, and some were positive
for Her4. A recent study suggested that neuronal cells
can be derived from ventricular ptf1a-expressing pro-
genitor cells.47 GFAP-positive radial glia cells can lead
to both neurons and oligodendrocystes.32 In addition,
Her4-positive ventricular progenitor cells proliferate
and generate neuronal cells.40 In the current model,
DAAkt1-induced gliomas were positive for GFAP and
Her4, and tumors were invariably located at the periven-
tricular area, where transgene expression was robust.
Growing tumors gradually invaded both the ventricle
and the granular layer of the cerebellum. Although the
cell origin of glioma is still enigmatic, if the ventricular
area is assumed to be a stem cell niche,42 the current
study suggests that gliomas arise from a subset of pro-
genitor cells expressing Ptf1a, Her4, and GFAP at the
ventricular zone.
The predominant tumor type in human cerebellum is,
in fact, medulloblastoma. The medulloblastoma differs
from glioma in genetics and cell origin:48 the hedgehog
and Wnt pathways play key roles in medulloblastoma,
whereas the Akt pathway plays a key role in gliomagen-
esis. The finding of only gliomagenesis in the current
and downregulation of E-cadherin. *P, 0.05. Mann-Whitney U test was used for statistical differences. Electrophoretic (B) and Western
blot (C) images confirm quantitative RT-PCR findings. C, control; A, Ptf1aGal4/UASGFP-UASDAAkt1 without tumor; A(T), Ptf1aGal4/
UASGFP-UASDAAkt1 with tumor; Ptf1aGal4/UASGFP-UASDAAkt1/UASGFP-DARac1 with tumor. (D) Expression analyses of differential genes by
IHC (c, g, i, k, l, n, p, and q) or ISH (a, b, d, e, f, h, j, m, o, and r). Dotted red lines indicate tumor boundaries. Gliomas coexpressing
DAAkt1 and DARac1 show stronger expression of survivin2, snail1a, b-catenin, and cyclin D1, especially at the hypercellular area (red
arrowheads). Expression of pan-cadherin and E-cadherin is downregulated in glioma coexpressing DARac1, especially at the higher-grade
area (* in p). Bars, 50 mm.
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Fig. 6. Treatment with Akt pathway inhibitors in groups of ptf1aGal4/UASGFP-UASDAAkt1 larvae. (A and B) Prolonged treatment from 2
weeks to 2 months. (A) Tumor incidence is significantly lowered by Akt1/2 inhibitor but not by miltefosine or rapamycin (x2 test). (B)
Expression of Akt1 downstream component. Untreated glioma cells express phospho-mTOR, -4EBP1, and RS6K, suggesting activation of
Akt1 signaling. Although rapamycin treatment decreased phospho-mTOR expression, miltefosine and Akt1/2 inhibitor decreased
phospho-RS6K expression. (C, D) Treatment in 3-month-old zebrafish with glioma. (C) Counted PCNA-positive cells from 10 high-power
fields are significantly lowered by treatment with rapamycin or Akt1/2 inhibitor (ANOVA test). (D) IHC analyses indicated increased cells
positive for active caspases in gliomas treated with Akt1/2 inhibitor and decreased cells positive for PCNA in gliomas treated with Akt1/
2 inhibitor or rapamycin. Bars, 50 mm.
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model suggests that the genetic events occurred in a spe-
cific cell type, with Akt activation being the major factor
determining tumor type. Although current models
develop gliomas, which are infrequent in cerebellum,
we believe these models also recapitulate gliomas occur-
ring in cerebrum at molecular and genetic levels and are
suitable for exploring mechanisms involved in glioma-
genesis by activated Akt pathway.
Current data suggest that the survival pathway played
a major role in the current model of AKT-induced glio-
magenesis for several reasons. First, RT-PCR showed
frank upregulation of survivin genes, which are
members of IAP family, whereas Eif1a was not upregu-
lated. Survivin genes regulate cell division and cell
death,44 protect cells against apoptosis,49 are highly
expressed in malignant glioma, and are also associated
with a poor prognosis.50 Activation of the Akt
pathway leads to survivin expression,51 and inhibition
of Akt induces downregulation of survivin.11
Akt-induced proliferation relies on mTOR protein,
whose activation leads to transcriptional activation of
Eif1a, which revealed subtle change on RT-PCR.
Second, when cellular proliferation was evaluated
before tumor development, DAAkt1 did not induce
widespread activation of downstream pathways or in-
creased proliferation in ptf1a-positive ventricular cells;
only established tumors did so. Third, although rapamy-
cin treatment in established tumors reduced the number
of PCNA-positive tumor cells and inhibited mTOR acti-
vation, gliomagenesis was not inhibited when larvae
were treated for long periods. Therefore, it is more plau-
sible that the survival pathway and not the proliferation
pathway played a major role in the current glioma
models.
The acceleration of gliomagenesis by coexpression of
DARac1 was quite striking. A series of in vitro and in
vivo studies suggested that activation of Rac promotes
the migratory and metastatic abilities of tumor cells by
enhancing EMT23,52 and also leads to an enhanced
nuclear localization of b-catenin, resulting in increased
cellular proliferation.53 Present data showed that coex-
pression of DARac1 not only enhanced tumor incidence
but also aggravated histologic grade and invasiveness of
glioma. On histologic evaluation, gliomas coexpressing
DAAkt1 and DARac1 frequently revealed a mixture of
low-grade and high-grade portions. The high-grade
area of glioma showed an increase in proliferative
markers accompanied by stronger expression of
DARac1 and downregulation of E-cadherin. DARac1
induced further increases in cyclin D1 and b-catenin ex-
pression and striking increases in survivin2 and snail1a.
Although Akt alone induces snail1 expression45,54 and
tumor progression through EMT,55–57 the above find-
ings indicate that Rac1 acts as an important player in
glioma progression by enhancing EMT and promoting
the survival and proliferation of glioma cells.
The current models can be a useful platform for the
screening and evaluation of small molecular drugs tar-
geting the Akt pathway. The zebrafish model provides
a unique opportunity for high throughput in vivo screen-
ing of anticancer candidate drugs, which is not feasible
in a mouse model. The feasibility of acquiring a toxicity
profile in a physiologic context is an additional benefit of
using the zebrafish as a model for drug screening. These
inherent advantages will allow cost-effective and high-
throughput in vivo study to search for effective small
molecules that target the Akt pathway. The current
model reflects the Akt1-induced enhancement of sur-
vival signaling and suggests that survivin is a promising
target for the treatment of glioma.
In summary, this study identifies novel functions of
Akt1 and Rac1 in the initiation and progression of glio-
magenesis in zebrafish. Overexpression of DAAkt1 is
sufficient to induce gliomagenesis through activation of
anti-apoptosis signals. Furthermore, we identified Rac1
as an important molecule involved in the progression
of glioma, which is mediated by enhanced EMT and a
boost in the activation of survival and proliferation
signaling. These transgenic models will be a valuable
platform for exploring the mechanisms of gliomagenesis
and may allow screening of potential targeted agents for
the treatment of glioma.
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